Form 4: BiomX Inc. Director Susan Blum Acquires Options in Company Stock

Director Susan Blum reports acquisition of options to purchase 17,600 shares of BiomX Inc. common stock.

Summary

• On April 14, 2025, Susan Blum, a director of BiomX Inc., acquired options to purchase 17,600 shares of the company's common stock at an exercise price of $0.538 per share.
• The options vest over four years, with 25% vesting on April 14, 2026, and the remaining portion vesting in 12 equal quarterly installments over three years.
• Following the transaction, Susan Blum directly owns options for 17,600 shares of BiomX Inc. common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition. The director's acquisition could be interpreted as a positive sign, but it's not explicitly stated.

Positives

• A director's acquisition of company stock options can be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule suggests a multi-year commitment.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Option grants are a common form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Option grants to directors are a common practice in publicly traded companies, particularly in the biotech sector, to align their interests with those of shareholders.
• The vesting schedule of four years with quarterly installments is fairly standard for executive compensation packages.
• Comparing the size of the option grant (17,600 shares) to similar companies would require analyzing their executive compensation disclosures.

Key Dates

Keywords

BiomX Inc., Susan Blum, options, stock options, director, acquisition, Form 4, PHGE, vesting